Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
P311
- Development stage
- Preclinical
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Administration
- Topical
01
Overview
P311, also known as Neuronal regeneration related protein (NREP) or Neural protein 3.1, is an 8 kDa intracellular protein/peptide that plays a significant role in tissue repair and regeneration. It promotes angiogenesis, re-epithelialization, and M2 macrophage polarization, which are crucial for effective wound healing. Its functions are mediated through interactions with several signaling pathways, including the TGF-βRII-Smad, Akt, and mTOR pathways, and by upregulating factors like the IL-4 receptor and vascular endothelial growth factor (VEGF). P311 is being investigated as a therapeutic agent, particularly in formulations like microspheres and micelles, to enhance wound healing.
- Other names
- Neuronal regeneration related proteinNREPNeural protein 3.1
02
Targets
CCL21 (Chemokine (C-C motif) ligand 21)HPRT1 (Hypoxanthine-guanine phosphoribosyltransferase)AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)MAPK3 (Mitogen-activated protein kinase 1)IL4R (Interleukin-4 receptor alpha subunit)STAT6 (Signal Transducer and Activator of Transcription 6)SMAD3 (SMAD family member 3)TGFB1 (Transforming growth factor Beta-1 proprotein)TGFBR2 (TGF-β receptor type 2)VEGFA (Vascular endothelial growth factor A)VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on P311.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on P311.